MX2015014344A - Terapia contra el cancer. - Google Patents
Terapia contra el cancer.Info
- Publication number
- MX2015014344A MX2015014344A MX2015014344A MX2015014344A MX2015014344A MX 2015014344 A MX2015014344 A MX 2015014344A MX 2015014344 A MX2015014344 A MX 2015014344A MX 2015014344 A MX2015014344 A MX 2015014344A MX 2015014344 A MX2015014344 A MX 2015014344A
- Authority
- MX
- Mexico
- Prior art keywords
- mycobacterium
- cancer therapy
- treatment
- cancer
- heatâ
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/542—Mucosal route oral/gastrointestinal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
- A61K2039/541—Mucosal route
- A61K2039/544—Mucosal route to the airways
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Communicable Diseases (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Dermatology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Otolaryngology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
Abstract
La presente invención concierne a la preparación de un medicamento para auxiliar en el tratamiento contra el cáncer. Según la invención, hay Mycobacterium de células completas para usarse en el tratamiento contra enfermedades neoplásicas siendo combinado con un inhibidor de mTOR, donde el Mycobacterium es un Mycobacterium muerto por calor y no patógeno.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1308325.8A GB201308325D0 (en) | 2013-05-09 | 2013-05-09 | Cancer Therapy |
PCT/GB2014/051421 WO2014181121A1 (en) | 2013-05-09 | 2014-05-09 | Cancer therapy |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015014344A true MX2015014344A (es) | 2016-06-21 |
Family
ID=48672024
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015014344A MX2015014344A (es) | 2013-05-09 | 2014-05-09 | Terapia contra el cancer. |
Country Status (18)
Country | Link |
---|---|
US (1) | US20160074494A1 (es) |
EP (1) | EP2994148B8 (es) |
JP (1) | JP2016520057A (es) |
KR (1) | KR20160022803A (es) |
CN (1) | CN105407901A (es) |
AU (1) | AU2014264434A1 (es) |
BR (1) | BR112015025719A2 (es) |
CA (1) | CA2907841A1 (es) |
DK (1) | DK2994148T3 (es) |
ES (1) | ES2618050T3 (es) |
GB (1) | GB201308325D0 (es) |
HU (1) | HUE031783T2 (es) |
MX (1) | MX2015014344A (es) |
PL (1) | PL2994148T3 (es) |
RU (1) | RU2015143106A (es) |
SG (1) | SG11201507847UA (es) |
SI (1) | SI2994148T1 (es) |
WO (1) | WO2014181121A1 (es) |
Families Citing this family (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB201120779D0 (en) | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
GB201322725D0 (en) | 2013-12-20 | 2014-02-05 | Immodulon Therapeutics Ltd | Cancer therapy |
US11207405B2 (en) * | 2015-06-24 | 2021-12-28 | Immodulon Therapeutics Limited | Checkpoint inhibitor and a whole cell Mycobacterium for use in cancer therapy |
KR101832892B1 (ko) * | 2015-08-24 | 2018-02-27 | 가톨릭대학교 산학협력단 | 면역억제제로 유발되는 미토콘드리아 질환 및 면역 질환의 예방 또는 치료를 위한 메트포민을 포함하는 조성물 |
GB201601248D0 (en) * | 2016-01-22 | 2016-03-09 | Immodulon Therapeutics Ltd | Cancer therapy |
GB201608806D0 (en) * | 2016-05-19 | 2016-07-06 | Immodulon Therapeutics Ltd | Method |
WO2018112360A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating cancer |
WO2018112364A1 (en) * | 2016-12-16 | 2018-06-21 | Evelo Biosciences, Inc. | Combination therapies for treating melanoma |
WO2019075452A1 (en) * | 2017-10-13 | 2019-04-18 | Evelo Biosciences, Inc. | IDENTIFICATION OF BACTERIA FOR CANCER THERAPY |
CN109329204B (zh) * | 2018-10-12 | 2021-02-12 | 中国医学科学院北京协和医院 | 胰腺癌动物模型的构建方法 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU4281200A (en) | 1999-04-23 | 2000-11-10 | Qlt Inc. | Immuno-adjuvant pdt treatment of metastatic tumors |
US20020022032A1 (en) | 1999-04-23 | 2002-02-21 | Curry Patrick Mark | Immuno-adjuvant PDT treatment of metastatic tumors |
WO2006109300A1 (en) | 2005-04-14 | 2006-10-19 | Hadasit Medical Research Services & Development Ltd. | Pre-transplantation treatment of donor cells to control graft versus host disease (gvhd) in transplant recipients |
WO2008110491A2 (en) * | 2007-03-09 | 2008-09-18 | University Of Basel | Chemotherapy of neoplastic diseases using combinations of rapamycin and compounds modulating mtor pathway alone or in combination with heat |
EP2085466A1 (en) * | 2008-01-29 | 2009-08-05 | AEterna Zentaris GmbH | Non-pathogenic and/or attenuated bacteria capable of inducing apoptosis in macrophages, process of manufacturing and uses thereof |
ES2567753T3 (es) * | 2009-07-08 | 2016-04-26 | Baltic Bio Ab | Derivados de 1,2,4-tiazolidin-3-ona y su uso en el tratamiento del cáncer |
GB201120779D0 (en) * | 2011-12-02 | 2012-01-11 | Immodulon Therapeutics Ltd | Cancer therapy |
US8617520B2 (en) * | 2012-02-15 | 2013-12-31 | Immodulon Therapeutics Limited | Cancer therapy |
-
2013
- 2013-05-09 GB GBGB1308325.8A patent/GB201308325D0/en not_active Ceased
-
2014
- 2014-05-09 EP EP14723864.6A patent/EP2994148B8/en not_active Not-in-force
- 2014-05-09 BR BR112015025719A patent/BR112015025719A2/pt not_active IP Right Cessation
- 2014-05-09 AU AU2014264434A patent/AU2014264434A1/en not_active Abandoned
- 2014-05-09 DK DK14723864.6T patent/DK2994148T3/en active
- 2014-05-09 RU RU2015143106A patent/RU2015143106A/ru not_active Application Discontinuation
- 2014-05-09 PL PL14723864T patent/PL2994148T3/pl unknown
- 2014-05-09 SG SG11201507847UA patent/SG11201507847UA/en unknown
- 2014-05-09 US US14/785,579 patent/US20160074494A1/en not_active Abandoned
- 2014-05-09 HU HUE14723864A patent/HUE031783T2/en unknown
- 2014-05-09 ES ES14723864.6T patent/ES2618050T3/es active Active
- 2014-05-09 SI SI201430160A patent/SI2994148T1/sl unknown
- 2014-05-09 MX MX2015014344A patent/MX2015014344A/es unknown
- 2014-05-09 WO PCT/GB2014/051421 patent/WO2014181121A1/en active Application Filing
- 2014-05-09 CN CN201480020906.8A patent/CN105407901A/zh active Pending
- 2014-05-09 KR KR1020157028621A patent/KR20160022803A/ko not_active Application Discontinuation
- 2014-05-09 JP JP2016512418A patent/JP2016520057A/ja active Pending
- 2014-05-09 CA CA2907841A patent/CA2907841A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2907841A1 (en) | 2014-11-13 |
EP2994148B8 (en) | 2017-08-30 |
EP2994148B1 (en) | 2017-02-01 |
PL2994148T3 (pl) | 2017-07-31 |
RU2015143106A (ru) | 2017-06-15 |
CN105407901A (zh) | 2016-03-16 |
JP2016520057A (ja) | 2016-07-11 |
WO2014181121A1 (en) | 2014-11-13 |
KR20160022803A (ko) | 2016-03-02 |
US20160074494A1 (en) | 2016-03-17 |
SI2994148T1 (sl) | 2017-07-31 |
DK2994148T3 (en) | 2017-03-13 |
HUE031783T2 (en) | 2017-07-28 |
ES2618050T3 (es) | 2017-06-20 |
AU2014264434A1 (en) | 2015-10-08 |
BR112015025719A2 (pt) | 2017-07-18 |
GB201308325D0 (en) | 2013-06-19 |
SG11201507847UA (en) | 2015-11-27 |
EP2994148A1 (en) | 2016-03-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015014344A (es) | Terapia contra el cancer. | |
TWD161529S (zh) | 治療燈 | |
MX2016007709A (es) | Un inhibidor de punto de control y una celula de mycobacterium para su utilizacion en el tratamiento contra cancer. | |
IN2015DN00895A (es) | ||
PH12014502048B1 (en) | Treatment of cancer with tor kinase inhibitors | |
NZ626954A (en) | Combination therapy of antibodies against human csf-1r and uses thereof | |
MX2015017201A (es) | Derivados de pirazolopiridina para uso en el tratamiento del cancer de vejiga. | |
EA201490194A1 (ru) | Комбинированная терапия, включающая ингибитор cdk4/6 и ингибитор pi3k для применения в лечении рака | |
NI201400112A (es) | Tratamiento del cáncer con inhibidores tor cinasa | |
MX2014012477A (es) | Inhibidores pirrolopirazona de tanquirasa. | |
MX2021001425A (es) | Compuestos terapeuticos activos y sus usos. | |
GEP201706612B (en) | Methods for the treatment of breast cancer | |
EP3046626A4 (en) | Treatment theater for proton therapy | |
MX2015014599A (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tracar cancer. | |
PH12015500169A1 (en) | Prediction of treatment response to jak/stat inhibitor | |
CR20140400A (es) | Terapia combinada para el tratamiento del cancer de ovario | |
AU2018253600A1 (en) | Dosage forms and therapeutic uses of l-4-chlorokynurenine | |
MX2015012444A (es) | Metodos de diagnostico, seleccion y tratamiento de enfermedades y afecciones provocadas por o asociadas con metanogenos. | |
MX2014010940A (es) | El uso de antitrombina en el tratamiento de preeclampsia. | |
PH12017500923A1 (en) | New dosage and use of a a2a antagonist | |
MX365192B (es) | Derivados de bendamustina y compuestos relacionados, y uso medico de los mismos para la terapia de cancer. | |
MX2014012535A (es) | Terapia de combinacion de anticuerpos anti-mif y quimioterapeuticos. | |
MX2018003801A (es) | Formulacion de hipericina para la terapia fotodinamica. | |
CR20140480A (es) | Metodos para tratar el cancer usando inhibidor de pi3k e inhibidor de mek | |
IN2014KN01772A (es) |